wavelifesciences.com (WVE): Net earnings per share (EPS TTM)
Trials of innovative RNA drugs are driving growth for Wave Life Sciences (WVE). The company relies on the PRISM platform, which creates unique stereopure molecules. However, the risk of clinical trial failure creates financial pressure, and the change in per-share profit over the last 12 months on GURU.Markets reflects this volatility, where the value -1.07 records this metric.
Metric breakdowns and analytics for Wave Life Sciences Corp (WVE)
- stock price and consensus target price:
- stock exchange capitalization data:
- business book valuation details:
- debt and solvency information:
Debt to Equity Wave Life Sciences|WVE - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital wavelifesciences.com|WVE - Company Total Debt|Debts to Book Capitalization Wave Life Sciences|WVE - Long-Term Debt Volume|Company Short-Term Debts Wave Life Sciences|Quick Liquidity wavelifesciences.com
- net income and valuation multiples indicators:
WVE - Company Profit|Projected Future Earnings Wave Life Sciences|WVE - Price to Earnings Ratio|Forward P/E Multiple wavelifesciences.com|WVE - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Wave Life Sciences|WVE - Operating income before deduction of amortization|Net earnings per share for the last 12 months Wave Life Sciences|WVE - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months wavelifesciences.com|WVE - Earnings per share growth in current year|Earnings growth forecast for next year Wave Life Sciences
- revenue and sales proceeds data:
Initial company analysis:Wave Life Sciences Ltd (WVE)
For the biotechnology sector, where Wave Life Sciences (WVE) is developing the PRISM platform for targeted CNS therapy, this indicator serves as a measure of innovation monetization efficiency. By analyzing the TTM net income per share, an investor sees the result of dividing the total annual income by the total number of securities, which allows for an assessment of the real return on capital and the fundamental stability of the business.
Competitors of Wave Life Sciences
TEM: Net earnings per share for the last 12 months|QGEN (Qiagen Group) - Earnings per share for the last 12 months|Ionis (IONS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Repligen Inc. (RGEN)|RNA (Avidity Biosciences) - Net earnings per share (EPS TTM)|CRSP (CRISPR Therapeutics AG) - Earnings per share for the last four quarters|Earnings per share for the last twelve months GeneDx (WGS)|RARE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) BEAM (Beam Therapeutics Inc)|Earnings per share for the trailing year SRPT|twistbioscience.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year TXG (10x Genomics, Inc.)|NTLA: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months STOK (Stoke Therapeutics, Inc.)|Net earnings per share for the last 12 months BLFS|Net earnings per share (EPS TTM) Maze Therapeutics Inc|Net earnings per share (EPS TTM) SION|PRME - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) TSHA (Taysha Corp)|Earnings per share for the trailing year QURE|MeiraGTx Holdings - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year REGENXBIO Corp (RGNX)|solidbio.com (SLDB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months OCGN|PACB (PacBio Corp) - Net earnings per share (EPS TTM)|BNTC: Earnings per share for the trailing year|Earnings per share for the last twelve months Design Corp (DSGN)|Net earnings per share for the last 12 months Rocket Pharmaceuticals Inc RCKT|FDMT: Net earnings per one share for the last twelve months|LXEO: Earnings per share for the last 12 months|Korro Bio, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Editas Medicine|Silence Therapeutics (SLN) - Earnings per share for the last twelve months|PRQR (ProQR Therapeutics N.V.) - Earnings per share for the last twelve months|CDXS (Codexis Inc) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months sangamo.com (SGMO)|Net earnings per share (EPS TTM) NAUT|Net earnings per share (EPS TTM) Metagenomi (MGX)|Earnings per share for the last twelve months Precision BioSciences DTIL|Net earnings per share (EPS TTM) Generation Bio Corp GBIO|Boundless Bio, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Exicure Inc.|Imunon, Inc. (IMNN) - Earnings per share for the last twelve months|RXi Pharmaceuticals (PHIO) - Net earnings per share (EPS TTM)|MBIO (Mustang Bio Corp) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months RNAZ (TransCode Therapeutics)|Net earnings per share (EPS TTM) BNGO|APDN: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) BLUE (bluebird bio Inc.)|Net earnings per share for the last four quarters ImmunoPrecise Antibodies (IPA)|OMGA: Net earnings per share for the last 12 months|OMIC (Singular Genomics Systems Inc) - Earnings per share for the last 12 months|Regulus Therapeutics (RGLS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months syros.com (SYRS)|TBIO (Telesis Bio Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months TRACON Pharmaceuticals Inc. (TCON)|Net earnings per share for the last 12 months UBX (Unity Biotechnology, Inc.)
